CHIRAL SWITCH- AN EMERGING STRATEGY IN THERAPEUTICS
AbstractDuring the last decade, drug chirality, more specifically the use of single enantiomers versus racemic mixtures has been in the forefront of discussions in scientific forums.This is because the left and right handed twins of a molecule behave quite differently from each other in a biological environment. This can frequently lead to an improvement in pharmacological and therapeutic profile of the molecule/drug. This understanding of the significance of stereo-chemistry coupled with advances in chemical technologies and further nudged by regulatory requirements has helped the increase in the development of individual isomers at the expense of racemic mixtures.Apart from the development of novel stereo-selective compounds, a number of racemates have been re-evaluated as potential single enantiomer agents with Â the possibility of an improved pharmacological/therapeutic profile. These have been termed as Chiral Switches and have resulted in the re-birth of a number of agents as single enantiomers and have provided significant improvements over the racemic drug. Economic considerations are also playing a part with pharmaceutical companies increasingly using chiral switching as a marketing strategy to increase the patent longevity and profitability period of a drug. However, not all these switches have resulted in therapeutic superiority and in many instances, unpredicted adverse reactions have resulted. Before a switch to clinical use of single enantiomers is made, physicians should satisfy themselves from evidence based on well-conducted clinical trials that the chiral switch is cost-effective and improves the outcomes for patients. Â KEY WORDS: Chirality, Chiral Switch, Enantiomers
Download data is not yet available.
261 Views | 362 Downloads
How to Cite
SHARMA S, SHARMA AK, GUPTA AK, DAHIYA N, BRASHIER DBS. CHIRAL SWITCH- AN EMERGING STRATEGY IN THERAPEUTICS. JDDT [Internet]. 14Mar.2014 [cited 26Oct.2021];4(2):135-9. Available from: http://jddtonline.info/index.php/jddt/article/view/794
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).